carmot glp 1 Roche Continues to Reap Rewards of Buyout with Strong Early GLP-1 Data Genentech: Carmot Therapeutics

Weight Loss Comparison: Injectable Semaglutide (Wegovy 2.4 mg weekly): Average weight loss: 14.9% of body weight Duration: 68 weeks Patients losing 5%+: 86.4% Patients losing 10%+: 69.1% Patients losing 15%+: 50.5% Injectable Tirzepatide (Zepbound 15 mg weekly): Average weight loss: 22.5% of body weight Duration: 72 weeks Patients losing 5%+: 96% Patients losing 10%+: 89% Patients losing 15%+: 78% Patients losing 20%+: 63% Oral Semaglutide (Rybelsus 14 mg daily): Average weight loss: 3-5% of body weight Duration: 26-52 weeks depending on study Patients losing 5%+: Approximately 30-40% Patients losing 10%+: Less than 10% Patients losing 15%+: Rare Real-World Weight Loss Examples: Starting Weight: 250 pounds Starting Weight: 200 pounds Why Such a Big Difference

Gonzlez-Noriega, C

One of the most frustrating parts of losing weight is that your lean muscle mass and strength can drop as well

I had a moment of FOMO, of not wanting to be left behind, she says

T.TorresV

Shi G, Jiang H, Feng J, Zheng X, Zhang D, Jiang C, et al